TL;DR
This study reveals a high prevalence of non-fatal opioid overdoses (NFOD) among people who use drugs (PWUD) in Massachusetts, highlighting specific drug use patterns and substances (like non-prescription buprenorphine and fentanyl) that significantly increase risk. These findings are crucial for informing targeted interventions to combat the ongoing opioid overdose epidemic.
What Problem Does This Paper Address?
The opioid overdose epidemic in the US has led to a devastating loss of life and significant economic costs. While fatal overdoses receive considerable attention, non-fatal overdoses (NFOD) are also a critical public health concern. Individuals who experience an NFOD are at a substantially higher risk of subsequent fatal overdoses. However, accurately tracking NFODs is challenging as they are often only reported when individuals seek medical services. This paper aims to address this gap by investigating the prevalence of NFOD and identifying associated factors among PWUD in Massachusetts, a state experiencing a surge in opioid-related deaths, particularly due to fentanyl. Understanding these correlates is essential for developing effective prevention and intervention strategies.
Methods
The researchers conducted a mixed-methods rapid assessment study in eight Massachusetts communities identified as having rising trends in fatal overdoses. For this paper, they focused on the quantitative data collected from 469 participants who use illicit drugs and were 18 years or older. Participants were recruited using non-probability sampling methods, including purposive, chain referral, and respondent-driven sampling. A one-time, interviewer-administered survey was used to collect data on sociodemographics, substance use patterns (including specific drugs and routes of administration), history of overdose experiences, and knowledge/access to naloxone. Statistical analyses included descriptive statistics, Chi-squared and Fisher exact tests for global differences, and multivariable logistic regression to identify factors associated with lifetime and past year NFOD.
Datasets
The study utilized data collected from 469 participants in Massachusetts between August 2017 and November 2019. This dataset is a primary data collection effort for this specific study and is not a publicly available benchmark dataset.
Key Insights and Ideas
- NFOD is alarmingly common: The study found that a significant majority of PWUD in Massachusetts have experienced at least one non-fatal overdose in their lifetime, and a substantial portion have had one in the past year. This underscores the pervasive nature of overdose risk within this population.
- Fentanyl and heroin are major drivers: The use of fentanyl and heroin, particularly when injected, is strongly associated with increased odds of both lifetime and past-year NFOD. This reinforces the critical role these substances play in the current overdose crisis.
- Non-prescription buprenorphine is a red flag: Interestingly, the use of non-prescription buprenorphine (obtained outside of a formal prescription) was independently associated with higher odds of NFOD. This suggests that individuals may be using it to self-manage withdrawal symptoms, potentially in the context of more severe opioid use or dependence.
- Marijuana as a potential protective factor: Conversely, marijuana use was associated with lower odds of lifetime NFOD. This finding, while needing further investigation, could suggest a role for cannabis in harm reduction or as a substitute for more dangerous substances.
- Naloxone access is important, but not a complete solution: While a high proportion of participants knew about and had access to naloxone, difficulty in obtaining it was associated with higher odds of lifetime NFOD. This highlights the need for improved and equitable access to this life-saving medication.
Key Results
- Prevalence: 62.5% of participants reported a lifetime NFOD, and 36.9% reported a past-year NFOD.
- Substance Use: 64% reported heroin use and 45% reported fentanyl use in the 30 days prior to the survey. Injection was the most common route of administration (59.5%).
- Risk Factors for Lifetime NFOD: Nonprescription buprenorphine and fentanyl use were independently associated with higher odds of lifetime NFOD. Marijuana use was associated with lower odds.
- Risk Factors for Past Year NFOD: Injection as a route of administration, benzodiazepine, nonprescription buprenorphine, heroin, and fentanyl use were independently associated with higher odds of past year NFOD. Methadone use was associated with lower odds.
- Naloxone: 97.2% knew about naloxone, and 62.7% had it with them at the time of the survey.
Limitations and Future Work
The authors acknowledge several limitations:
- Generalizability: The study focused on high-overdose-risk communities in Massachusetts, so findings may not be generalizable to other regions.
- Self-Report Bias: Data relied on self-report, which is susceptible to recall and reporting biases. The absence of substance use testing means participants might have unknowingly used fentanyl-contaminated drugs.
- Oversampling: The high rate of naloxone possession might be due to oversampling of participants from substance use treatment and harm reduction centers.
- Data Granularity: Exact dates of care and health events were not obtained, limiting precise timing analysis.
- Temporal Relationship: The cross-sectional design prevents establishing definitive cause-and-effect relationships.
- Changing Patterns: Substance use patterns may have changed over the extended study period (2017-2019).
- Mental Health: The study did not assess mental health issues, which could be a significant factor in overdose risk.
Future research directions suggested include exploring behavioral health considerations more broadly, investigating the motivations behind using prescribed, non-prescribed, and illicit substances in relation to overdose risk, and further examining the role of marijuana in harm reduction. The authors also emphasize the need for improved access to medication for opioid use disorders (MOUD) and naloxone, as well as addressing equity in access to harm reduction supplies.
Summary updated